rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
4
|
pubmed:dateCreated |
2007-3-15
|
pubmed:abstractText |
Liposomal amphotericin B (LAmB) has demonstrated similar efficacy to conventional amphotericin B for antifungal treatment in patients with febrile neutropenia; however, it is not without toxicities and is associated with a high acquisition cost. Despite this high cost, LAmB has been shown to have a pharmacoeconomic advantage over less expensive agents. Voriconazole is a potential alternative for empirical antifungal treatment of febrile neutropenia. The objective of this study was to assess the economic outcomes of voriconazole versus LAmB in patients with fever and neutropenia.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1173-2563
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
27
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
233-41
|
pubmed:meshHeading |
pubmed-meshheading:17358095-Amphotericin B,
pubmed-meshheading:17358095-Antifungal Agents,
pubmed-meshheading:17358095-Decision Support Techniques,
pubmed-meshheading:17358095-Economics, Pharmaceutical,
pubmed-meshheading:17358095-Fever,
pubmed-meshheading:17358095-Health Care Costs,
pubmed-meshheading:17358095-Humans,
pubmed-meshheading:17358095-Liposomes,
pubmed-meshheading:17358095-Neutropenia,
pubmed-meshheading:17358095-Pyrimidines,
pubmed-meshheading:17358095-Retrospective Studies,
pubmed-meshheading:17358095-Treatment Outcome,
pubmed-meshheading:17358095-Triazoles
|
pubmed:year |
2007
|
pubmed:articleTitle |
Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia.
|
pubmed:affiliation |
Department of Pharmacy Services, University of Michigan Health System, Ann Arbor, MI 48109-0008, USA. cdcollin@umich.edu
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|